Estimated numbers and prevalence of PI*S and PI*Z alleles of alpha1-antitrypsin deficiency in European countries.
about
Hereditary alpha-1-antitrypsin deficiency and its clinical consequencesChallenges and Prospects for Alpha-1 Antitrypsin Deficiency Gene TherapyCosts and health-related quality of life in Alpha-1-Antitrypsin Deficient COPD patients.Treatment of lung disease in alpha-1 antitrypsin deficiency: a systematic review.Serum concentration of alpha-1 antitrypsin is significantly higher in colorectal cancer patients than in healthy controls.Deterioration of quality of life is associated with the exacerbation frequency in individuals with alpha-1-antitrypsin deficiency - analysis from the German Registry.Alpha-1 antitrypsin Pi*SZ genotype: estimated prevalence and number of SZ subjects worldwide.Z α1-antitrypsin confers a proinflammatory phenotype that contributes to chronic obstructive pulmonary diseaseDetermination of alpha-1 antitrypsin level in patients with severe asthma.Severe alpha-1 antitrypsin deficiency in composite heterozygotes inheriting a new splicing mutation QOMadridThe shapes of Z-α1-antitrypsin polymers in solution support the C-terminal domain-swap mechanism of polymerization.Efficacy of alpha1-antitrypsin augmentation therapy in conditions other than pulmonary emphysema.Reglucosylation by UDP-glucose:glycoprotein glucosyltransferase 1 delays glycoprotein secretion but not degradation.Therapy with plasma purified alpha1-antitrypsin (Prolastin®) induces time-dependent changes in plasma levels of MMP-9 and MPO.Prevalence of α-1-antitrypsin gene mutations in Saudi Arabia.The prevalence of alpha-1 antitrypsin deficiency in IrelandWhy has it been so difficult to prove the efficacy of alpha-1-antitrypsin replacement therapy? Insights from the study of disease pathogenesisRapid and inexpensive detection of alpha1-antitrypsin deficiency-related alleles S and Z by a real-time polymerase chain reaction suitable for a large-scale population-based screeningClinical heterogeneity and potential high pathogenicity of the Mmalton Alpha 1 antitrypsin allele at the homozygous, compound heterozygous and heterozygous states.Prevalence of PI*Z and PI*S alleles of alpha-1-antitrypsin deficiency in FinlandAlpha-1-antitrypsin deficiency in Serbian adults with lung diseases.The selective advantage of alpha1-antitrypsin deficiency.Alpha-1 Antitrypsin Deficiency PI*Z and PI*S Gene Frequency Distribution Using on Maps of the World by an Inverse Distance Weighting (IDW) Multivariate Interpolation Method.Chronic obstructive pulmonary disease in Hispanics.Diagnosis of alpha-1 antitrypsin deficiency: a population-based study.Results from a large targeted screening program for alpha-1-antitrypsin deficiency: 2003 - 2015.Development and results of the Spanish registry of patients with alpha-1-antitrypsin deficiency.Selected metabolic aspects of elastin and collagen fiber proteolysis in diseases of the respiratory system - the significance of α1 antitrypsin deficiency.Augmentation therapy for emphysema due to alpha-1-antitrypsin deficiency.Emerging drugs for alpha-1-antitrypsin deficiency.Lung deposition of inhaled alpha-1-proteinase inhibitor (alpha 1-PI) - problems and experience of alpha1-PI inhalation therapy in patients with hereditary alpha1-PI deficiency and cystic fibrosisThe role of proteases, endoplasmic reticulum stress and SERPINA1 heterozygosity in lung disease and α-1 anti-trypsin deficiency.Prevalence of α1-antitrypsin deficiency alleles PI*S and PI*Z worldwide and effective screening for each of the five phenotypic classes PI*MS, PI*MZ, PI*SS, PI*SZ, and PI*ZZ: a comprehensive review.Molecular diagnostics of α1-antitrypsin deficiency.Alpha-1 antitrypsin deficiency in Iranian patients with chronic obstructive pulmonary disease.Alpha-1-antitrypsin deficiency: increasing awareness and improving diagnosis.Alpha-1 antitrypsin Pi*Z gene frequency and Pi*ZZ genotype numbers worldwide: an update.Advances in Identifying Urine/Serum Biomarkers in Alpha-1 Antitrypsin Deficiency for More Personalized Future Treatment Strategies.PCR-based screening for the most prevalent alpha 1 antitrypsin deficiency mutations (PI S, Z, and Mmalton) in COPD patients from Eastern Tunisia.Recent advances in understanding and treating COPD related to α1-antitrypsin deficiency.
P2860
Q21202920-A5BFA7B1-45E3-4143-B019-A1212E6F9C79Q28080450-6C890383-3DD7-4E71-A5E1-4B08724B45C9Q33568562-91B0D133-4844-4781-9B83-B3531C760F3AQ33649874-EE70DD2D-7611-43DA-B259-264FC6929319Q33656312-9FE876E0-CB86-47C9-A4EE-DF9967FE08A0Q33713789-7FFD6786-3C67-467B-AF5D-5C52BEDEFC6DQ33806741-B3387478-6EA0-4FE8-BCF9-2B791C47A5DBQ33901639-368A88F0-0D93-4D35-B1FD-0940459EE91AQ34126916-459F26AE-DA75-4127-AF72-07D8D0B795ECQ34325994-10DC3E1D-2C07-476A-8E7E-D5999E784582Q34424129-AD8BE5F8-DBC6-468E-8AD9-C40170D3BC9DQ34980209-E6D0802A-644E-488E-97F3-93449B90377AQ35027539-604F78F6-4697-4463-AFED-5CAA299F88B7Q35031693-59ABA226-736F-469F-8495-8D8154274299Q35098361-78E9A7E6-5E3A-450B-930C-4A73A2388756Q35162540-F3F5CF22-8CB0-4B27-8BC0-9223E11F0319Q35233352-7F8F62F1-9C5A-41B6-BA36-74A864625704Q35789532-0088CE82-3A35-4682-A2AF-588488D8CC5EQ36131624-35CD0619-DFEC-4800-912F-23C02210830DQ36300621-3BF41E2E-CD2F-4682-A186-FE98955EAEF0Q36353172-206832C6-4A45-478F-B93B-312DCE587DB9Q36378692-D8124E80-8FA6-4F33-AB1A-F3CAA2D99D80Q36407173-1CD5A304-5A18-49AB-BF68-43C366E3B69BQ36482639-55132D59-B551-43A7-9D72-1854C4EAEC0CQ36907960-A4BD7594-30F6-454F-9241-334B32995E7AQ36991312-7EE4AC73-144E-4CB6-9BD0-919E31235377Q37224486-219306A2-8389-4EAB-9062-809400BCE2BCQ37352149-03B9B416-6366-4455-8546-BF76A70A4322Q37362591-9769502F-8DCD-471A-B2D6-293507A8D4D0Q37780552-EF77FEBE-6C7B-4108-BFC4-CC5E0C945906Q37819431-4199A59D-0FDD-4E0D-8FA8-AC42D68B9D15Q37894093-F4E687F9-30D0-4112-90C3-9AAD54C2EFC2Q38039045-492D65D7-0627-48AB-B968-5D109D15048CQ38089248-1E3120CC-C7E1-4CC6-939F-6BD131B5F18AQ38580571-59B2F9F2-F9BD-4451-8792-47A8B321EA4AQ38581002-D9BF71AD-D52F-4121-9FA1-80EC89E3A791Q38752547-A81C4764-104C-4931-9EA0-317699F5D01DQ38797163-BBAE6EE9-A321-4EA5-A23E-FD65E09CBB35Q38969996-837E204D-4A36-4624-998A-6D4287BE1B33Q38988633-2AC9C9F6-5111-4DCC-BB73-8F7054592984
P2860
Estimated numbers and prevalence of PI*S and PI*Z alleles of alpha1-antitrypsin deficiency in European countries.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Estimated numbers and prevalen ...... iciency in European countries.
@ast
Estimated numbers and prevalen ...... iciency in European countries.
@en
Estimated numbers and prevalen ...... iciency in European countries.
@nl
type
label
Estimated numbers and prevalen ...... iciency in European countries.
@ast
Estimated numbers and prevalen ...... iciency in European countries.
@en
Estimated numbers and prevalen ...... iciency in European countries.
@nl
prefLabel
Estimated numbers and prevalen ...... iciency in European countries.
@ast
Estimated numbers and prevalen ...... iciency in European countries.
@en
Estimated numbers and prevalen ...... iciency in European countries.
@nl
P2093
P1476
Estimated numbers and prevalen ...... ficiency in European countries
@en
P2093
E Fernandez-Bustillo
F J de Serres
P356
10.1183/09031936.06.00062305
P577
2006-01-01T00:00:00Z